Patents Represented by Attorney Janice E. Williams

Find this attorney in the Justia Lawyer Directory

  • Method for the preparation of bacterial clones carrying optimal genetic information for the production of the factor for release of human growth hormone in Escherichia coli
    Patent number: 4857470
    Abstract: The DNA coding for human recombinant growth hormone releasing factor (GRF) cloned into a bacterial plasmid expression vector by assembling in one step selected synthetic DNA fragments.
    Type: Grant
    Filed: January 8, 1985
    Date of Patent: August 15, 1989
    Assignee: Smith Kline-RIT, s.a.
    Inventors: Alfredo J. Morais Cravador, Paul Jacobs, Alex J. Bollen, Ary Van Elsen, Albert A. M. Herzog
  • Fluorescent intracellular calcium indicators
    Patent number: 4849362
    Abstract: Invented are new tetracarboxylate compounds which are chelators for calcium ions. Also invented is a useful method of measuring intracellular calcium concentrations using these novel compounds as an optical indicator.
    Type: Grant
    Filed: May 19, 1988
    Date of Patent: July 18, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Robert M. DeMarinis, Haralambos E. Katerinopoulos, Katharine A. Muirhead
  • Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
    Patent number: 4847270
    Abstract: Novel compounds, pharmaceutical compositions and a method of inhibiting the 5-lipoxygenase products in an animal in need thereof which comprises administering an effective, 5-lipoxygenase pathway inhibiting amount of a 2,2'-[1,2-ethanediylbis-(thio)]-bis-1H-imidazole or 2,2'-[1,3-propan-2-onediylbis-(thio)]bis-1H-imidazole, or a pharmaceutically acceptable salt thereof, to such animal.
    Type: Grant
    Filed: November 10, 1987
    Date of Patent: July 11, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Paul E. Bender, David T. Hill
  • Polynucleotide hybridization probes
    Patent number: 4840892
    Abstract: Polynucleotide hybridization probes are labeled in non-probe regions but not in probe regions by selectively protecting probe regions prior to modification of the polynucleotide.
    Type: Grant
    Filed: April 15, 1985
    Date of Patent: June 20, 1989
    Assignee: Smithkline Beckman Corporation
    Inventors: Craig W. Adams, Jeffry J. Leary, Martin Rosenberg
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4837353
    Abstract: 2-(N-Phenylakyl-N-formyl)amino-3-hydroxy-2-propenoic acids are intermediates for mercaptoimidazolecarboxylic acids which are dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: January 21, 1988
    Date of Patent: June 6, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Joseph A. Finkelstein, Lawrence I. Kruse, Thomas B. Leonard
  • Hybrid polypeptides comprising somatocrinine and alpha.sub.1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
    Patent number: 4828988
    Abstract: A fusion between DNA sequences coding for hAT and hGRF via a synthetic adaptor coding for an in vitro cleavable amino acid sequence is used to express hGRF at high levels in E. coli.
    Type: Grant
    Filed: May 15, 1986
    Date of Patent: May 9, 1989
    Assignee: Smith Kline - RIT
    Inventors: Alex J. Bollen, Paul Jacobs
  • 4'-Methyl-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid vasopressin antagonists
    Patent number: 4826813
    Abstract: Vasopressin antagonists which have a 4'-methyl-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid group have vasopressin antagonist activity without substantial agonist activity. A species of the invention is [1-(4'-methyl-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-arginine]vasopressin.
    Type: Grant
    Filed: May 21, 1987
    Date of Patent: May 2, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: William F. Huffman, Nelson C. F. Yim
  • Sulfinyl and sulfonyl substituted 2,3,4,5 tetrahydro-1H-3-benzazepines and their use in treating gastrointestinal motility disorders
    Patent number: 4824839
    Abstract: Sulfinyl and sulfonyl substituted 3-benzazepine compounds are useful in treating gastrointestinal motility disorders and emesis. A particular compound of this invention is 7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine.
    Type: Grant
    Filed: March 14, 1988
    Date of Patent: April 25, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: William E. Bondinell, Herbert S. Ormsbee, III
  • Pyrrolidone derivatives and memory enhancement use thereof
    Patent number: 4824861
    Abstract: The invention relates to 4-hydroxy pyrrolidone derivatives which help restore learning and memory difficulties associated with ageing. A compound of the invention is 2-(4-hydroxy-2-oxo-1-pyrrolidineacetamido)acetamide.
    Type: Grant
    Filed: December 11, 1987
    Date of Patent: April 25, 1989
    Assignee: ISF Societa Per Azioni
    Inventors: Mario Pinza, Carlo Farina, Silvano Banfi, Ugo Pfeiffer
  • 5-phenyl-3[2H]-pyridazinone derivatives
    Patent number: 4820819
    Abstract: This invention relates to (isopropyl and tertiary butyl-amino-2-hydroxypropoxy)phenyl-3[2H]-pyridazinones which have .beta.-adrenoceptor antagonist activity.
    Type: Grant
    Filed: March 20, 1987
    Date of Patent: April 11, 1989
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Anthony M. Roe, William J. Coates, Robert A. Slater, Stephen P. Breukelman
  • Leukotriene antagonists
    Patent number: 4820719
    Abstract: This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.
    Type: Grant
    Filed: May 16, 1988
    Date of Patent: April 11, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: John G. Gleason, Ralph F. Hall, Thomas Wen-Fu Ku, Carl D. Perchonock
  • Quinate salts of antimalarial phenanthrenemethanol compounds
    Patent number: 4818767
    Abstract: The compounds of formula (I) ##STR1## wherein R.sub.1 is hydrogen or an alkyl radical containing one to six carbon atoms and R.sub.2 is an alkyl radical containing one to six carbon atoms possess markedly increased activity against malaria-causing parasites. Pharmaceutical compositions and method of treatment of subjects with malaria are also disclosed.
    Type: Grant
    Filed: November 2, 1983
    Date of Patent: April 4, 1989
    Assignee: SmithKline Beckman Corporation
    Inventor: Jean F. Rossignol
  • Pharmaceutically active compounds
    Patent number: 4812573
    Abstract: The invention relates to a class of tetrahydroisoquinolinylalkanoic acids containing an aryl sulphonamide group which have activity as thromboxane A.sub.2 antagonists.
    Type: Grant
    Filed: June 27, 1988
    Date of Patent: March 14, 1989
    Assignee: SmithKline & French Laboratories, Ltd.
    Inventors: Graham J. Durant, Andrew D. Gribble, Robert A. Slater
  • Intermediates for preparing 1,6-dicarba-vasopressin compounds
    Patent number: 4810778
    Abstract: New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by the Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.
    Type: Grant
    Filed: May 9, 1988
    Date of Patent: March 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Kenneth A. Newlander, Nelson C. F. Yim
  • Dopamine-beta-hydroxylase inhibitors
    Patent number: 4810811
    Abstract: The compounds of this invention are 1-phenylalkyl-2-mercaptotetrazole compounds which are dopamine-.beta.-hydroxylase inhibitors.
    Type: Grant
    Filed: August 24, 1987
    Date of Patent: March 7, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Carl Kaiser, Lawrence I. Kruse
  • Pyrimidone derivatives
    Patent number: 4808589
    Abstract: This invention provides 5-substituted-4-pyrimidones having in the 2-position a heterocyclic (or substituted phenyl) alkyl group. These compounds have histamine H.sub.2 -antagonist activity.
    Type: Grant
    Filed: February 9, 1983
    Date of Patent: February 28, 1989
    Assignee: Smith Kline & French Laboratories Limited
    Inventor: Thomas H. Brown
  • 4-amino-3-carbonyl substituted quinolines
    Patent number: 4806549
    Abstract: This invention relates to novel substituted 4-aminoquinoline derivatives which are inhibitors of gastric acid secretion in mammals. A compound of the invention is 3-butyryl-4-(2-methylphenylamino)-8-methoxyquinoline.
    Type: Grant
    Filed: September 3, 1987
    Date of Patent: February 21, 1989
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Robert J. Ife, Thomas H. Brown, Colin A. Leach
  • Vaccine formulation
    Patent number: 4806350
    Abstract: A highly immunogenic aqueous vaccine formulation adjuvanted with a saponin and an oil.
    Type: Grant
    Filed: April 18, 1986
    Date of Patent: February 21, 1989
    Assignee: Norden Laboratories, Inc.
    Inventor: Jay D. Gerber
  • 4-Amino-3-carbonyl substituted quinolines as inhibitors of gastric acid secretion
    Patent number: 4806550
    Abstract: This invention relates to novel substituted 4-aminoquinoline derivatives which are inhibitors of gastric acid secretion in mammals. A compound of the invention is 3-butyryl-4-(2-methylphenylamino)-8-methoxyquinoline.
    Type: Grant
    Filed: May 12, 1988
    Date of Patent: February 21, 1989
    Assignee: SmithKline & French Laboratories Limited
    Inventors: Robert J. Ife, Thomas H. Brown, Colin A. Leach
  • 2-mercaproimidazole dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4798843
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutial compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: July 9, 1987
    Date of Patent: January 17, 1989
    Assignee: SmithKline Beckman Corporation
    Inventor: Lawrence I. Kruse